Screener
Immunome IMNM Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Immunome in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Immunome’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:10 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219425
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Depreciation and amortization | 603 | 611 |
| Amortization of right-of-use asset | 150 | 115 |
| Accretion of discounts on marketable securities | — | (818) |
| Share-based compensation expense | 7,953 | 5,703 |
| Loss on disposal of property and equipment | 79 | — |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other assets | (5,098) | (1,707) |
| Accounts payable | 1,421 | (3,810) |
Item 1. Financial Statements.
FAQ
- What is Immunome's stock-based comp?
- Immunome (IMNM) reported stock-based comp of $7.95M in Q1 2026.
- How has Immunome's stock-based comp changed year-over-year?
- Immunome's stock-based comp increased by 39.5% year-over-year, from $5.7M to $7.95M.
- What is the long-term trend for Immunome's stock-based comp?
- Over 4 years (2021 to 2025), Immunome's stock-based comp has grown at a 65.2% compound annual growth rate (CAGR), from $3.45M to $25.69M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Immunome's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude